January 10, 2025 Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers read more
CTAD 2024 Quanterix Fireside Chat with Henrik Zetterburg: Advances in Blood-Based Biomarkers for Alzheimer’s Disease read more
May 17, 2024 Q&A: Blood-based biomarker testing ‘scientific consensus favorite’ for AD detection read more
January 26, 2024 Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer’s Disease Pathology read more
October 3, 2023 Ultrasensitive immunoassay technology drives blood-based biomarkers for Alzheimer’s disease read more
December 2, 2024 CTAD 2024 Fuels the Momentum in Advancing Alzheimer’s Disease Detection & Treatment with a Spotlight on Blood-Based Biomarkers read more
October 3, 2024 Insights from ECTRIMS 2024: Exploring MS Biomarkers and the Role of Quanterix read more